Clinical Trial Search

Primary: Saphenous Vein Graft Occlusion (Percentage of Vein Grafts Occluded) Based on CT Coronary Angiography at 1 Year — 14; 16 Vein grafts

Primary: Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis at Week 12 Measure: PASI 75 (Psoriasis Area and Severity…

Primary: The Mean Annualized Change in eGFR From Pretreatment Baseline to Post-treatment Follow-up. — -2.339; -3.610 mL/min/1.73 m^2/year — p=<0.0001

Primary: Clinician Assessment of Change From Baseline in Redness at 60 Seconds After First Product Application — 0.31; 0.27; 0.32 units on a scale — p=0.392

Primary: Number of Participants With Adverse Events — 374; 374; 30; 41 Participants

Primary: Number of Participants Who Were Clinically Well-controlled (UAS7<=6) After the Initial Dosing Period, Relapsed (UAS7>=16) When Treatment Was Discontinued, and Who…

Primary: Percentage of Patients Who Experienced at Least One System-generated Error Based on the Controller Data While Using the Zalviso System — 2.2 percentage of patients

Primary: Period 1: Clinical and Endoscopic Remission — 87; 95 Participants — p=0.005

Primary: Primary Efficacy Outcome MACE Events — 905; 839 Participants — p=0.061

Primary: Change From Baseline in NRS Pain Intensity — -0.24 units on a scale

Primary: Number of Seroprotected Subjects With Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibodies — 1418; 717; 1439; 728 Participants

Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 Strain of Influenza Disease — 383.6; 339.1 Titers

Primary: Forced Expiratory Volume — 4 percentage of predicted

Primary: Percent Change From Baseline in High-density Lipoprotein C (HDL-C) Levels After 4 Weeks of Treatment — 43.8; 10.1 Percentage raise in HDL-C Levels

Primary: Percentages of Subjects With Human Serum Bactericidal Antibody (hSBA) Seroresponse Against Neisseria Meningitidis Serogroups A, C, W and Y. — 97.97; 97.01; 97.50; 64.71…